Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.43 |
| ▸ | PGR | P06401 | 1/20 | 0.43 |
| ▸ | EBP | Q15125 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29617949 | 1.00 | KDM1A (0.56) | KDM1AMEN1KMT2AAKR1B1SIGMAR1 | |
| SCHEMBL7384590 | 0.94 | KDM1A (0.50) | KDM1AMEN1KMT2ASIGMAR1MAP2K1 | |
| SCHEMBL3941515 | 0.88 | KDM1A (0.46) | KDM1ASIGMAR1MAP2K1MAPK1SMN1; SMN2 | |
| SCHEMBL19130582 | 0.88 | KDM1A (0.46) | KDM1ASIGMAR1MAP2K1MAPK1SMN1; SMN2 | |
| Ammonia Solution, Strong SCHEMBL10600738 | 0.86 | KDM1A (0.44) | KDM1ASIGMAR1MAP2K1MAPK1SMN1; SMN2 | |
| Methyl Alcohol SCHEMBL14815563 | 0.80 | KDM1A (0.56) | KDM1AMEN1KMT2AAKR1B1SIGMAR1 | |
| SCHEMBL31629514 | 0.79 | KDM1A (0.50) | KDM1AMEN1KMT2AAKR1B1SIGMAR1 | |
| SCHEMBL578812 | 0.79 | KDM1A (0.59) | KDM1AMEN1KMT2AAKR1B1SIGMAR1 | |
| SCHEMBL4195493 | 0.79 | KDM1A (0.50) | KDM1AMEN1KMT2AAKR1B1SIGMAR1 | |
| SCHEMBL29556050 | 0.79 | KDM1A (0.59) | KDM1AMEN1KMT2AAKR1B1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2938341-B1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2018-09-05 | — | — | EP | disclosed |
| US-9884844-B2 | Heterocyclic compounds and methods of use thereof | SUNOVION PHARMACEUTICALS, INC. (US) | 2018-02-06 | — | — | US | disclosed |
| US-9884844-B2 | Heterocyclic compounds and methods of use thereof | SUNOVION PHARMACEUTICALS, INC. (US) | 2018-02-06 | — | — | US | disclosed |
| US-9884844-B2 | Heterocyclic compounds and methods of use thereof | SUNOVION PHARMACEUTICALS, INC. (US) | 2018-02-06 | — | — | US | disclosed |
| US-20150336928-A1 | Heterocyclic Compounds And Methods Of Use Thereof | SUNOVION PHARMACEUTICALS INC. | 2015-11-26 | — | — | US | disclosed |
| US-20150336928-A1 | Heterocyclic Compounds And Methods Of Use Thereof | SUNOVION PHARMACEUTICALS INC. | 2015-11-26 | — | — | US | disclosed |
| US-20150336928-A1 | Heterocyclic Compounds And Methods Of Use Thereof | SUNOVION PHARMACEUTICALS INC. | 2015-11-26 | — | — | US | disclosed |
| EP-2938341-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | Sunovion Pharmaceuticals Inc. (US) | 2015-11-04 | — | — | EP | disclosed |
| WO-2014106238-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | FANG, QUN, KEVIN (US) | 2014-07-03 | — | — | WO | disclosed |
| WO-2014106238-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | FANG, QUN, KEVIN (US) | 2014-07-03 | — | — | WO | disclosed |
| US-6307085-B1 | E.G., 3-METHOXY-3-(4-PHENYLPHENYL)BUT-1-YL BIS(4-PHENYLPHENYL)PHOSPHATE | POLAROID CORPORATION | 2001-10-23 | — | — | US | disclosed |
| US-6242154-B1 | GENERATION OF ACID | POLAROID CORPORATION | 2001-06-05 | — | — | US | disclosed |
| US-6110638-A | Process and composition for generation of acid | POLAROID CORPORATION (US) | 2000-08-29 | — | — | US | disclosed |
| US-6015907-A | PHOTOSTABLE IMAGING DYES FOR ACID-MEDIATED MEDIA, ALSO FOR PHOTOSENSITIZING ONIUM SALTS TO VISIBLE BLUE RADIATION | POLAROID CORPORATION (US) | 2000-01-18 | — | — | US | disclosed |
| EP-0951661-A4 | — | — | 1999-11-17 | — | — | EP | disclosed |
| EP-0951661-A1 | PROCESS AND COMPOSITION FOR GENERATING ACID | POLAROID CORPORATION (US) | 1999-10-27 | — | — | EP | disclosed |
| US-5914213-A | MIXTURE; THERMAL DECOMPOSITION; IMAGE MEDIUM | POLAROID CORPORATION (US) | 1999-06-22 | — | — | US | disclosed |
| WO-1998024000-A1 | PROCESS AND COMPOSITION FOR GENERATING ACID | POLAROID CORPORATION (US) | 1998-06-04 | — | — | WO | disclosed |
| US-5294618-A | Psychological disorders | MERCK SHARP & DOHME LIMITED (GB) | 1994-03-15 | — | — | US | disclosed |
| EP-0410535-A2 | Octahydrobenzisoquinoline derivatives as antipsychotic agents | MERCK SHARP & DOHME LTD. (GB) | 1991-01-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150336928-A1 | Heterocyclic Compounds And Methods Of Use Thereof | GRIN2C, COMT, NLN | KDM1A 3995/4885MEN1 2159/4885KMT2A 2037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.